187 related articles for article (PubMed ID: 25255063)
1. Beyond C, H, O, and N! Analysis of the elemental composition of U.S. FDA approved drug architectures.
Smith BR; Eastman CM; Njardarson JT
J Med Chem; 2014 Dec; 57(23):9764-73. PubMed ID: 25255063
[TBL] [Abstract][Full Text] [Related]
2. Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery.
Ilardi EA; Vitaku E; Njardarson JT
J Med Chem; 2014 Apr; 57(7):2832-42. PubMed ID: 24102067
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Small Ions with Capillary Electrophoresis.
Aulakh JS; Kaur R; Malik AK
Methods Mol Biol; 2016; 1483():197-216. PubMed ID: 27645739
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals.
Vitaku E; Smith DT; Njardarson JT
J Med Chem; 2014 Dec; 57(24):10257-74. PubMed ID: 25255204
[TBL] [Abstract][Full Text] [Related]
5. [The refractory susceptibility in determination of sulfur in organic drugs using the Schoniger method].
Listov SA; Arsamastsev AP; Gamanina GJ
Pharmazie; 1988 Oct; 43(10):686-9. PubMed ID: 3212013
[TBL] [Abstract][Full Text] [Related]
6. Analysis of US FDA-Approved Drugs Containing Sulfur Atoms.
Scott KA; Njardarson JT
Top Curr Chem (Cham); 2018 Jan; 376(1):5. PubMed ID: 29356979
[TBL] [Abstract][Full Text] [Related]
7. Highlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023.
Ali S; Bolinger AA; Zhou J
Curr Top Med Chem; 2024; 24(10):843-849. PubMed ID: 38445700
[TBL] [Abstract][Full Text] [Related]
8. AM1* parameters for phosphorus, sulfur and chlorine.
Winget P; Horn AH; Selçuki C; Martin B; Clark T
J Mol Model; 2003 Dec; 9(6):408-14. PubMed ID: 12955599
[TBL] [Abstract][Full Text] [Related]
9. U.S. FDA Approved Drugs from 2015-June 2020: A Perspective.
Bhutani P; Joshi G; Raja N; Bachhav N; Rajanna PK; Bhutani H; Paul AT; Kumar R
J Med Chem; 2021 Mar; 64(5):2339-2381. PubMed ID: 33617716
[TBL] [Abstract][Full Text] [Related]
10. Isotope fractionation in aqua-gas systems: Cl(2)-HCl-Cl(-), Br(2)-HBr-Br(-) and H(2)S-S(2-).
Czarnacki M; Hałas S
Isotopes Environ Health Stud; 2012; 48(1):55-64. PubMed ID: 22092223
[TBL] [Abstract][Full Text] [Related]
11. [Use of x-ray fluorescence analysis for determination of bromine in drug synthesis, with a look at chlorine (sulfur) and fluorine].
Sanner G; Usbeck H
Pharmazie; 1985 Aug; 40(8):544-8. PubMed ID: 4080799
[TBL] [Abstract][Full Text] [Related]
12. Powerful, transferable representations for molecules through intelligent task selection in deep multitask networks.
Fare C; Turcani L; Pyzer-Knapp EO
Phys Chem Chem Phys; 2020 Jun; 22(23):13041-13048. PubMed ID: 32478374
[TBL] [Abstract][Full Text] [Related]
13. From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles.
Delost MD; Smith DT; Anderson BJ; Njardarson JT
J Med Chem; 2018 Dec; 61(24):10996-11020. PubMed ID: 30024747
[TBL] [Abstract][Full Text] [Related]
14. Clinical and regulatory features of drugs not initially approved by the FDA.
Wang B; Avorn J; Kesselheim AS
Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
[TBL] [Abstract][Full Text] [Related]
15. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
16. Persistence of pharmaceuticals and other organic compounds in chlorinated drinking water as a function of time.
Gibs J; Stackelberg PE; Furlong ET; Meyer M; Zaugg SD; Lippincott RL
Sci Total Environ; 2007 Feb; 373(1):240-9. PubMed ID: 17188338
[TBL] [Abstract][Full Text] [Related]
17. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
18. (1)H and (13)C NMR spectral assignments of halogenated transformation products of pharmaceuticals and related environmental contaminants.
Solakyildirim K; Bulloch DN; Larive CK
Magn Reson Chem; 2014 Jun; 52(6):310-7. PubMed ID: 24691899
[No Abstract] [Full Text] [Related]
19. The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770706
[TBL] [Abstract][Full Text] [Related]
20. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
Xu K; Coté TR
Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
